In Oncology, Drug Makers Jostle For Second Place
Executive Summary
A look at top players now and potential changes in the next six years.
You may also be interested in...
Novartis Thinks It Can Do Better With GSK’s Oncologics Than GSK Did
Novartis stresses the blockbuster potential, in its hands, of three products – Votrient, Tafinlar and Mekinist – that it is acquiring from GSK as part of its narrowed focus on innovative pharmaceuticals, eye care and generics, and the divestment of vaccines, OTCs and animal health.
Novartis Thinks It Can Do Better With GSK’s Oncologics Than GSK Did
Novartis stresses the blockbuster potential, in its hands, of three products – Votrient, Tafinlar and Mekinist – that it is acquiring from GSK as part of its narrowed focus on innovative pharmaceuticals, eye care and generics, and the divestment of vaccines, OTCs and animal health.
As Sun Sets On Gleevec, Novartis Looks To New Horizons In Oncology
The blockbuster leukemia drug will likely face generic competition in 2015, putting pressure on Novartis to bring new cancer drugs to market to make up for the lost sales. The company has several promising mid- to late-stage candidates in the pipeline, but developing another blockbuster the likes of Gleevec won’t be easy.